A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2495655 in Japanese Subjects
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Landogrozumab (Primary) ; Landogrozumab (Primary)
- Indications Cachexia; Muscular atrophy; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 04 Dec 2014 New trial record